Antivir Ther by Lara, James & Khudyakov, Yury
Epistatic connectivity among hepatitis C virus genomic sites as 
genetic marker of interferon resistance
James Lara1 and Yury Khudyakov1
1Molecular Epidemiology & Bioinformatics Laboratory, Division of Viral Hepatitis, Centers for 
Disease Control and Prevention, Atlanta, GA
Abstract
The current standard-of-care therapy of patients with hepatitis C virus (HCV) infection involves 
treatment with interferon (IFN) and ribavirin. Host demographic and genetic factors as well as 
HCV genetic heterogeneity were shown to be associated with outcomes of therapy. Although 
resistance to IFN/RBV remains to be an important clinical and public health problem, there are no 
reliable genetic markers for the prediction of the therapy outcomes. Recently, it was shown that 
adaptation to IFN, a major constituent of the host innate immunity, is reflected in the HCV genetic 
composition and epistatic connectivity among polymorphic genomic sites, thus providing novel 
genetic markers of IFN resistance. Consideration of coordinated evolution among HCV genomic 
sites allows for the identification of these genetic markers from short regions of the HCV genome 
and accurate prediction of the therapy outcomes. The HCV genomic coevolution offers a general 
framework for the detection of predisposition to IFN resistance, and to resistance to direct-acting 
antivirals when they become introduced.
Introduction
Hepatitis C virus (HCV) belongs to family Flaviviridae and contains positive-sense, single-
stranded RNA genome of ~9600 nucleotides long. The HCV genome encodes a polyprotein 
that is processed into three structural proteins: core, E1 and E2, and seven non-structural 
proteins, P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B [1]. HCV is the major etiologic 
agent of blood-borne non-A, non-B hepatitis [2]. Approximately 60%–85% of HCV-infected 
patients fail to clear the virus and develop chronic hepatitis C (CHC) infection. CHC is a risk 
factor for the development of cirrhosis and liver cancer [3]. At present, there is no vaccine 
against HCV.
The current standard-of-care therapy for CHC involves a 24- or 48-week course of treatment 
with pegylated α-interferon (IFN) combined with ribavirin (RBV) [4, 5]. Because only 
40%–80% of CHC patients develop sustained virologic response (SVR) to this treatment [4–
6] and because patient intolerance to such therapy is common, knowing the therapy outcome 
before initiation of treatment is a major patient management objective. Recently, the 
IFN/RBV therapy was supplemented with HCV protease inhibitors, telaprevir or boceprevir 
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[7]. Effectiveness of treatment with these direct-acting antiviral agents (DAA) is reduced, 
however, in null responders to IFN/RBV therapy, especially among patients infected with 
HCV subgenotype 1a [8]. Until resistance to IFN is relevant to CHC therapy, detection of 
the resistance remains clinically important. Additionally, since IFN is a main component of 
the innate immune system [9], IFN resistance essentially defines HCV virulence. Therefore, 
monitoring for IFN resistance among HCV-infected populations is a public health objective.
Several factors are associated with HCV susceptibility to IFN/RBV treatment. HCV 
genotype is one of the most important factors. There are six major HCV genotypes, 1–6, 
with genotype 1 being the most prevalent genotype worldwide [10]. Patients infected with 
genotype 2 achieve SVR in 70%–80% of cases after treatment with IFN/RBV [5, 11]. In 
contrast, only 40%–52% of genotype 1-infected patients achieve SVR [6, 11]. The 
dependence of IFN/RBV response rates on genotype suggests that the HCV genetic 
composition is an essential factor affecting therapy outcome. Host factors also have been 
implicated. Genetic polymorphisms in the host, e.g., in the IL28B locus, play a role in 
defining the rate of spontaneous clearance [12] and IFN/RBV SVR [13, 14]. In addition, the 
patient’s gender, ethnicity and age have been observed to be associated with varied 
responses to INF/RBV [15].
Because innate immunity is one of the major host selection pressures, HCV has evolved 
multifaceted mechanisms to avert IFN actions [16], with HCV lineages varying in their 
capacity to withstand extraneous IFN. The complexity of HCV interaction with host 
immunity significantly impedes understanding of what underlies susceptibility to IFN, 
which in turn hampers discovery of reliable genetic markers of IFN resistance and 
development of diagnostic assays for the detection of the resistance.
HCV genetic heterogeneity and IFN/RBV resistance
The mechanisms of IFN or RBV action against HCV are not fully understood. Studies have 
shown that treatment with IFN activates the host’s innate antiviral immune responses by 
inducing IFN-stimulated genes [17, 18]. For RBV, several mechanisms of therapeutic action 
have been proposed, including viral mutagenesis induction [19], IMPDH inhibition [20], 
mRNA methylation inhibition [21] and facilitation of Th1-medited immunoresponses [22]. 
Feld and colleagues [23] recently reported that combined treatment with this nucleoside 
analog improves early responses to IFN, thus supporting its role in enhancing IFN signaling 
[24] and emphasizing the leading role of IFN in combination therapy.
IFN-inducible, double-stranded, RNA-activated protein kinase R (PKR) is known to be 
involved in the IFN-induced antiviral response [25]. Two HCV protein domains, the PKR-
eIFα phosphorylation homology domain (PePHD) of the E2 protein and the PKR-binding 
domain located in the C-terminal region of NS5A, have been implicated in binding to PKR 
[26]. Genetic heterogeneity within these domains was suggested to be related to IFN 
resistance. The E2 PePHD of IFN-resistant strains were observed to share greater similarity 
to the autophosphorylation sites of PKR and the phosphorylation site of the translation 
initiation factor (eIFα) than variants susceptible to IFN [26]. This similarity was greater for 
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HCV genotype 1 than genotype 2 or 3. However, these findings have not been supported in 
other studies [27, 28], indicating that PePHD is not a reliable marker of IFN resistance.
Sequence analysis of HCV genotype 1b showed that a 40 amino-acid stretch in the NS5A, 
known as the IFN sensitivity determining region (ISDR), was associated with the IFN 
therapy response. The number of mutations in ISDR was found to correlate with response to 
IFN therapy [29–31], thus suggesting that ISDR may be used as a genetic marker of IFN 
resistance. However, these findings were refuted in other studies [32, 33]. Castelain and 
colleagues [34] observed no binding between PKR and the genotype 3a NS5A from IFN-
resistant HCV strains. Moreover, intra-host HCV variants sharing the ISDR sequence were 
found to display differential susceptibility to IFN/RBV treatment [30]. Similar observations 
for HCV quasispecies sharing PePHD sequence [29] suggest that genetic diversity at regions 
other than ISDR and PePHD may be responsible for IFN resistance.
Particular variations at various genomic regions have been reported to be associated with 
differences in IFN/RBV susceptibility among HCV strains [16]. Specific mutations in the E2 
[35], core [29, 36, 37], NS2 [29, 35], NS5A [29, 35, 38], NS5B [16, 35] and p7 [35, 39] 
were found to correlate with response to IFN/RBV therapy. Although detectable, these 
genetic associations were inconsistent among HCV strains. Changes in mutation rates 
corresponding to IFN response were observed in some regions of the HCV genome, 
including E2 [40, 41], NS5A [31, 36], P7 [39] and NS2 [42]. However, no strong linkage 
between the HCV genetic diversity and IFN/RBV sensitivity has been detected [29, 32, 33, 
36, 38]. All these observations indicate a complex association between HCV genetic 
variability and response to IFN/RBV treatment. Resistance to IFN is most probably defined 
by variation at many HCV genomic sites rather than by specific mutations in a particular 
genomic region. Such a genetic basis of IFN resistance considerably hinders identification of 
HCV genomic markers for prediction of outcomes of IFN/RBV therapy.
Coordinated evolution of the HCV genome
Host selection pressures shape HCV evolution. Since innate immunity exerts one of the most 
intensive selection pressures on viruses, HCV evolution is significantly defined by IFN 
actions. Therefore, adaptation to IFN should be reflected in the HCV genetic composition 
and epistatic connectivity among polymorphic genomic sites. Epistasis plays a very 
important role in viral evolution [43, 44] and development of drug resistance [45]. Pervasive 
epistatic connectivity among viral genomic sites is frequently detected in the form of 
compensatory substitutions [45, 46]. This widespread connectivity is organized into a 
network of coordinated substitutions, reflecting extensive global coevolution among sites 
across the entire HCV genome [47]. The network has a very specific topology, with only a 
few sites being connected to many other sites and many sites having only a few connections.
Global coordination among HCV sites indicates that selection pressures acting at one site are 
distributed to other sites according to their degree and strength of connectivity in the 
network. Thus, selection affecting sites with many connections should have a much greater 
effect on the network state than selection at sites with very few connections. Taking into 
consideration that several HCV proteins are involved in mitigating IFN-mediated antiviral 
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activity [41], it should be expected that coevolution among many sites across the entire HCV 
genome is linked to selection pressures exerted by IFN. Indeed, recent studies showed that 
the topology of networks of coordinated substitutions is different for HCV strains that are 
resistant or sensitive to IFN/RBV treatment [48] and coevolution among sites in each HCV 
protein is associated with IFN response [49].
Coevolution and genetic markers of IFN/RBV response
Genetic analysis of IFN/RBV resistance is frequently focused on host or viral markers 
separately. It seems reasonable to assume that, since host provides the environment for viral 
replication, it should play a dominant role in controlling outcomes of HCV infection. 
Accrued data strongly support the essential contribution of host genetic variation to 
outcomes of IFN/RBV therapy [15]. There is also an equally large body of evidence 
supporting the crucial role of HCV genetic heterogeneity in overcoming antiviral actions of 
extraneous IFN [29–31, 36, 37, 39–42]. However, it is only recently that the integrative 
framework of host-virus interactions in the form of coevolution among HCV genomic sites 
was considered for the identification of genetic markers of IFN/RBV response [48–50].
As mentioned previously, coordinated evolution among HCV genomic sites reflects many 
host selection pressures, including innate and adaptive immune responses [47–50], thus 
associating host and viral genetic factors. Analysis of individual genomic sites without 
consideration of their interrelationships is inefficient for the detection of this association. 
There is no one mutation responsible for IFN resistance. Rather, genome-wide coordination 
among HCV sites is strongly linked to IFN response and can serve as a complex genetic 
marker of the resistance [49].
Examination of the entire HCV genome to assess the state of the genome-wide coordination 
is clearly impractical in clinical and public health settings. However, the extensive epistatic 
connectivity discovered among HCV genomic sites [47–49] suggests that coevolution 
among sites in any genomic region reflects selection pressures acting on the entire HCV 
genome in an infected host. Indeed, it was recently reported that each HCV protein [48, 49] 
or small genomic region, such as hypervariable region 1 (HVR1) and a segment of the NS5A 
gene [50], has a strong association with IFN resistance.
Although all HCV proteins were found to contribute sites into the network of coordinated 
substitutions associated with IFN response, the topological properties of sites differed 
among proteins [49] and, therefore, their involvement in IFN resistance. Two proteins, E2 
and NS5A, contributed ~40% of all sites and ~62% of all links to the HCV genome-wide 
network and effectively defined the state of the entire network [49]. The full-length 
sequences [49] or small regions [49, 50] of these proteins were used to predict outcomes of 
IFN/RBV therapy with 83%–90% accuracy. Interpretation of epistatic connectivity within 
these 2 regions into IFN/RBV resistance was achieved using mathematical models that 
associated various combinations of nucleotides or amino acids at the specifically selected 
HCV sites with therapy outcomes.
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The HCV IFN resistance is a complex phenotypic trait defined by many host and viral 
factors. Contribution of these factors to the outcome of IFN/RBV therapy can be 
mathematically modeled based on coordinated substitutions within the HCV genome. 
Coevolution among HCV sites offers novel genetic indicators of IFN/RBV resistance, which 
nonetheless are detectable using specially devised computational models. Complex genetic 
markers comprising more than one site are commonly formulated as “signatures” or 
“profiles”. Although assuming interrelationships among sites, such formulation obscures the 
underlying epistatic connectivity and encourages search for the combination of specific 
nucleotides or amino acids at certain genomic or protein positions that predicts the desirable 
phenotypic trend. Because predisposition to IFN resistance is encoded in the complex 
genome-wide interactions among numerous sites, the vast number of possible genomic 
“signatures” can be expected. Identification of all “signatures” is daunting but integration of 
all relevant “signatures” may be achieved by formulation of IFN resistance as a function of 
epistatic connectivity. Mathematical modeling of this connectivity presents a valuable 
opportunity for accurate prediction of the IFN/RBV therapy outcomes [49, 50].
When possible, reduction of “signatures” to a single site presents the best option for 
molecular detection because of simplicity of the genetic testing. However, detection of 
interrelationships among several genomic sites suitable for the accurate prediction of IFN 
resistance should not be any more complex than detection of polymorphism at a single site. 
Recent findings indicate that sequencing of short regions of the HCV genome provides 
sufficient information for the prediction of therapy outcomes [50]. Complexity of the 
sequence interpretation into IFN resistance requires the application of accurate mathematical 
models that translate interrelationships among genomic sites in novel genetic markers.
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